3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
5
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Melanoma
3
Uveal Melanoma
1
Urologic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
22
Nivolumab
17
Magnetic Resonance Spectroscopy
12
Specimen Handling
10
Cyclophosphamide
9
Radiosurgery
7
Drug Therapy
6
Radiotherapy
5
Paclitaxel
5
Ipilimumab
5
fludarabine
4
Biopsy
4
trametinib
3
sargramostim
3
Trastuzumab
3
Taxes
3
Pemetrexed
3
Metformin
3
Interleukin-2
3
Immunoglobulin G
3
Gemcitabine
3
Carboplatin
3
Bevacizumab
3
tremelimumab
2
temsirolimus
2
poly ICLC
2
pertuzumab
2
osimertinib
2
motexafin gadolinium
2
epacadostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
niraparib
×
Dermatologic
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts